Tuesday, March 26, 2019
2:30-4:00 PM Eastern Time
Immune responses are controlled by an exquisite system of stimulatory and inhibitory checkpoints. Cancer cells often find a way to utilize these checkpoints to avoid being attacked by the immune system. Checkpoint inhibitors, mainly targeting the adaptive immune system, are clinically available for use against certain types of cancer. Now, new therapeutics utilizing the innate immune system to jumpstart the effects of the adaptive system are currently in development. The innate immune system itself also expresses checkpoint molecules that have been shown to either enhance or dampen antitumor immunity. There is growing interest in blocking inhibitory innate immune checkpoints such as the “don’t eat me” signal CD47, which is commonly overexpressed on cancer cells, and the TAM receptor family of tyrosine kinases. Moreover, small molecule agonists against STING – a protein that ramps up production of interferons and cytokines – are major targets on the radar for therapeutic development, as well as molecules that target Toll-like Receptors (TLRs) and RIG-I-like Receptors (RLRs). Join us for a discussion about first-in-class STING agonists and innate immune checkpoints in cancer, and bring your questions and comments.
Topics to be covered:
- Immune Oncology beyond PD1: preclinical and first clinical data using ADU-S100, a first-in-class STING agonist
- Mechanism of an immune-modulating biologic for late-stage cancer
- The CD47-SIRPα innate immune checkpoint in cancer
Meet the Speakers:
Andrea van Elsas, PhD
Chief Scientific Officer
Aduro Biotech, Inc.
Jeremy R Graff, PhD
President and Chief Scientific Officer
Biothera Pharmaceuticals, Inc.
Timo van den Berg, PhD
Professor (Immunotherapy), Dept. Molecular Cell Biology and Immunology
VU Medical Center
Head, Dept. Blood Cell Research, Sanquin Research
Academic Medical Center